within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC19_Beraprost;

model Beraprost
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.6,
    Cl = 5.833333333333334e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.17,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004333333333333333,
    Tlag = 19.8,
    Vdp = 0.31,
    k12 = 1.866666666666667e-05,
    k21 = 1.866666666666667e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Beraprost</td></tr><tr><td>ATC code:</td><td>B01AC19</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>170</td><td>L</td></tr>
    <tr><td>clearance:</td><td>21</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Beraprost is an orally active prostacyclin analog used primarily as a vasodilator for the treatment of pulmonary arterial hypertension (PAH) and peripheral arterial disease. It acts by inhibiting platelet aggregation and inducing vasodilation. While approved for use in Japan and some Asian countries, it is not currently approved by the US FDA or EMA.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose</p><h4>References</h4><ol><li><p>Galiè, N, et al., &amp; Branzi, A (2003). Prostanoids for pulmonary arterial hypertension. <i>American journal of respiratory medicine : drugs, devices, and other interventions</i> 2(2) 123–137. DOI:<a href=\"https://doi.org/10.1007/BF03256644\">10.1007/BF03256644</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14720012/\">https://pubmed.ncbi.nlm.nih.gov/14720012</a></p></li><li><p>Nakajo, I, et al., &amp; Shiramoto, M (2021). Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males. <i>Clinical drug investigation</i> 41(6) 549–555. DOI:<a href=\"https://doi.org/10.1007/s40261-021-01031-8\">10.1007/s40261-021-01031-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33913081/\">https://pubmed.ncbi.nlm.nih.gov/33913081</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.B.B01AC19 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Beraprost;
